NewsBenzingaIovanceの第2相試験におけるリフィルセル+ペムブロリズマブは、進行性メラノーマの一次治療で奏効率62.5%、完全奏効率29.2%を示し、50.9か月時点でも全生存期間中央値は未到達 Iovanceの第2相試験におけるリフィルセル+ペムブロリズマブは、進行性メラノーマの一次治療で奏効率62.5%、完全奏効率29.2%を示し、50.9か月時点でも全生存期間中央値は未到達 Benzinga 2026.10.23 14:18 (GMT+0) Open on Benzinga Other news Is Wall Street Bullish or Bearish on Ferguson Enterprises Stock? Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket Reported Earlier, 'Leak of 15mn Deutsche Bank files exposes systemic failures; Email, internal probes and other documents throw new light on the career and leadership of chief executive Christian Sewing' - FT Exclusive Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment Weibo Q3 Adj. EPS $0.06 Misses $0.24 Estimate, Sales $410.230M Miss $417.238M Estimate Jensen Huang Ran Nvidia Like a 'Family Business' — Where Daughter Madison and Son-In-Law Held Growing Power Amid Workplace Complaints: Report
Reported Earlier, 'Leak of 15mn Deutsche Bank files exposes systemic failures; Email, internal probes and other documents throw new light on the career and leadership of chief executive Christian Sewing' - FT Exclusive
Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment
Jensen Huang Ran Nvidia Like a 'Family Business' — Where Daughter Madison and Son-In-Law Held Growing Power Amid Workplace Complaints: Report